News headlines about Dr. Reddy’s Laboratories (NYSE:RDY) have trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Dr. Reddy’s Laboratories earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.7091362707801 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Shares of NYSE:RDY opened at $32.47 on Tuesday. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.50 and a quick ratio of 1.13. Dr. Reddy’s Laboratories has a fifty-two week low of $29.83 and a fifty-two week high of $42.97. The firm has a market cap of $5,357.92, a P/E ratio of 29.25 and a beta of 0.28.

How to Become a New Pot Stock Millionaire

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its earnings results on Thursday, January 25th. The company reported $0.41 earnings per share for the quarter. Dr. Reddy’s Laboratories had a net margin of 6.95% and a return on equity of 8.79%. The firm had revenue of $596.00 million during the quarter. research analysts anticipate that Dr. Reddy’s Laboratories will post 1.07 earnings per share for the current year.

A number of equities analysts recently weighed in on the stock. ValuEngine upgraded shares of Dr. Reddy’s Laboratories from a “sell” rating to a “hold” rating in a research report on Monday, April 2nd. Zacks Investment Research upgraded shares of Dr. Reddy’s Laboratories from a “sell” rating to a “hold” rating in a research report on Monday, April 2nd. Two analysts have rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $30.51.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Dr. Reddy’s Laboratories (RDY) Share Price” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations.

Insider Buying and Selling by Quarter for Dr. Reddy`s Laboratories (NYSE:RDY)

Receive News & Ratings for Dr. Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories and related companies with's FREE daily email newsletter.